Cargando…

Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells

Primary Ovarian Insufficiency (POI) refers to an ovarian loss of function in women under the age of 40. Unfortunately, currently, there is no effective treatment available for POI-related infertility. Alternatives such as the use of egg donations are culturally and ethically unacceptable to many cou...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Hang-Soo, Ashour, Dalia, Elsharoud, Amro, Chugh, Rishi Man, Ismail, Nahed, EL Andaloussi, Abdeljabar, Al-Hendy, Ayman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269190/
https://www.ncbi.nlm.nih.gov/pubmed/32494757
http://dx.doi.org/10.24966/srdt-2060/100019
_version_ 1783541735215857664
author Park, Hang-Soo
Ashour, Dalia
Elsharoud, Amro
Chugh, Rishi Man
Ismail, Nahed
EL Andaloussi, Abdeljabar
Al-Hendy, Ayman
author_facet Park, Hang-Soo
Ashour, Dalia
Elsharoud, Amro
Chugh, Rishi Man
Ismail, Nahed
EL Andaloussi, Abdeljabar
Al-Hendy, Ayman
author_sort Park, Hang-Soo
collection PubMed
description Primary Ovarian Insufficiency (POI) refers to an ovarian loss of function in women under the age of 40. Unfortunately, currently, there is no effective treatment available for POI-related infertility. Alternatives such as the use of egg donations are culturally and ethically unacceptable to many couples. Human Bone marrow-derived Mesenchymal Stem Cells (MSCs) are known for their ability to differentiate into other cell types, once primed by the organ microenvironment. Importantly MSCs produce a vast array of bioactive factors many of them have been shown to enhance neovascularization in various tissues. Recently, preliminary data from our ongoing clinical trial revealed encouraging preliminary data after autologous MSC engraftment into the ovaries of 2 POI patients with durable elevation in serum estrogen levels and increase in size of treated ovaries sustained up to one-year post cell therapy. In this study, we investigated the action of the mechanisms of MSCs treatment on a POI ovary. We designed an in vitro study using MSC secretome and Human Ovarian Endothelial Cells (HOVECs) to understand the molecular mechanisms by which MSC mediates their angiogenic properties and regenerative effects. Human primary HOVECs were treatment with MSC secretome and examined by FACS for the expression of angiogenesis markers such as Endoglin, Tie-2, and VEGF. The formation of vessels was evaluated by using a 3D Matrigel tubulogenesis assay. We observed that the expression of proliferation marker Ki67 was significantly increased under treatment with MSC secretome in HOVEC cells (P4). MSCs secretome treatment also induced significantly higher expression of several angiogenic markers such as VEGFR2, Tie2/Tek, VE-Cadherin, Endoglin, and VEGF compared to matched control (P4). Furthermore, MSC secretome significantly increased the number of branching points in tubulogenesis assay (P4). Our study suggests that MSC secretome likely contains bioactive factors that can enhance ovarian angiogenesis. Further characterization of these factors can lead to novel therapeutic options for women with premature ovarian insufficiency and other related causes of female infertility.
format Online
Article
Text
id pubmed-7269190
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-72691902020-06-03 Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells Park, Hang-Soo Ashour, Dalia Elsharoud, Amro Chugh, Rishi Man Ismail, Nahed EL Andaloussi, Abdeljabar Al-Hendy, Ayman HSOA J Stem Cells Res Dev Ther Article Primary Ovarian Insufficiency (POI) refers to an ovarian loss of function in women under the age of 40. Unfortunately, currently, there is no effective treatment available for POI-related infertility. Alternatives such as the use of egg donations are culturally and ethically unacceptable to many couples. Human Bone marrow-derived Mesenchymal Stem Cells (MSCs) are known for their ability to differentiate into other cell types, once primed by the organ microenvironment. Importantly MSCs produce a vast array of bioactive factors many of them have been shown to enhance neovascularization in various tissues. Recently, preliminary data from our ongoing clinical trial revealed encouraging preliminary data after autologous MSC engraftment into the ovaries of 2 POI patients with durable elevation in serum estrogen levels and increase in size of treated ovaries sustained up to one-year post cell therapy. In this study, we investigated the action of the mechanisms of MSCs treatment on a POI ovary. We designed an in vitro study using MSC secretome and Human Ovarian Endothelial Cells (HOVECs) to understand the molecular mechanisms by which MSC mediates their angiogenic properties and regenerative effects. Human primary HOVECs were treatment with MSC secretome and examined by FACS for the expression of angiogenesis markers such as Endoglin, Tie-2, and VEGF. The formation of vessels was evaluated by using a 3D Matrigel tubulogenesis assay. We observed that the expression of proliferation marker Ki67 was significantly increased under treatment with MSC secretome in HOVEC cells (P4). MSCs secretome treatment also induced significantly higher expression of several angiogenic markers such as VEGFR2, Tie2/Tek, VE-Cadherin, Endoglin, and VEGF compared to matched control (P4). Furthermore, MSC secretome significantly increased the number of branching points in tubulogenesis assay (P4). Our study suggests that MSC secretome likely contains bioactive factors that can enhance ovarian angiogenesis. Further characterization of these factors can lead to novel therapeutic options for women with premature ovarian insufficiency and other related causes of female infertility. 2019-11-06 2019 /pmc/articles/PMC7269190/ /pubmed/32494757 http://dx.doi.org/10.24966/srdt-2060/100019 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Park, Hang-Soo
Ashour, Dalia
Elsharoud, Amro
Chugh, Rishi Man
Ismail, Nahed
EL Andaloussi, Abdeljabar
Al-Hendy, Ayman
Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells
title Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells
title_full Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells
title_fullStr Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells
title_full_unstemmed Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells
title_short Towards Cell free Therapy of Premature Ovarian Insufficiency: Human Bone Marrow Mesenchymal Stem Cells Secretome Enhances Angiogenesis in Human Ovarian Microvascular Endothelial Cells
title_sort towards cell free therapy of premature ovarian insufficiency: human bone marrow mesenchymal stem cells secretome enhances angiogenesis in human ovarian microvascular endothelial cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7269190/
https://www.ncbi.nlm.nih.gov/pubmed/32494757
http://dx.doi.org/10.24966/srdt-2060/100019
work_keys_str_mv AT parkhangsoo towardscellfreetherapyofprematureovarianinsufficiencyhumanbonemarrowmesenchymalstemcellssecretomeenhancesangiogenesisinhumanovarianmicrovascularendothelialcells
AT ashourdalia towardscellfreetherapyofprematureovarianinsufficiencyhumanbonemarrowmesenchymalstemcellssecretomeenhancesangiogenesisinhumanovarianmicrovascularendothelialcells
AT elsharoudamro towardscellfreetherapyofprematureovarianinsufficiencyhumanbonemarrowmesenchymalstemcellssecretomeenhancesangiogenesisinhumanovarianmicrovascularendothelialcells
AT chughrishiman towardscellfreetherapyofprematureovarianinsufficiencyhumanbonemarrowmesenchymalstemcellssecretomeenhancesangiogenesisinhumanovarianmicrovascularendothelialcells
AT ismailnahed towardscellfreetherapyofprematureovarianinsufficiencyhumanbonemarrowmesenchymalstemcellssecretomeenhancesangiogenesisinhumanovarianmicrovascularendothelialcells
AT elandaloussiabdeljabar towardscellfreetherapyofprematureovarianinsufficiencyhumanbonemarrowmesenchymalstemcellssecretomeenhancesangiogenesisinhumanovarianmicrovascularendothelialcells
AT alhendyayman towardscellfreetherapyofprematureovarianinsufficiencyhumanbonemarrowmesenchymalstemcellssecretomeenhancesangiogenesisinhumanovarianmicrovascularendothelialcells